Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract |
| |
| Authors: | G Palmieri L Montella C Aiello F Barbieri D Di Vizio S Schulz S Beninati A Budillon M Caraglia L Insabato T Florio |
| |
| Institution: | (1) Department of Molecular and Clinical Endocrinology and Oncology, “Federico II” University, Naples, Italy;(2) Pharmacology and Neuroscience, National Institute for Cancer Research, Genova, Italy;(3) Section of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy;(4) Department of Biomorphological and Functional Science, Unit of Pathology, University “Federico II”, Naples, Italy;(5) Department of Pharmacology and Toxicology, Otto-von-Guericke-University, Magdeburg, Germany;(6) Department of Biology, Second University of Rome “Tor Vergata”, Rome, Italy;(7) Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours “G. Pascale”, Naples, Italy |
| |
| Abstract: | Summary. Imatinib, a tyrosine kinase inhibitor directed against the enzymatic domain of KIT protein, was found to produce dramatic
clinical responses in metastatic gastrointestinal stromal tumors (GISTs). However, resistance usually develops thus determining
treatment failure. The present study was performed to analyse the expression of somatostatin receptor (SSTR) subtypes, modulators
of tissue transglutaminase, in a series of GISTs and leiomyosarcomas by immunohistochemistry to identify a new potential therapeutic
target. Sixteen cases (8 males and 8 females, age range: 38–73; 11 GISTs, 4 leiomyosarcomas, 1 leiomyoma) were studied. Immunohistochemical
detection of the relevant SSTRs was performed on paraffin-embedded tissue sections, stained with polyclonal antibodies directed
against the five somatostatin receptor subtypes. We found 7 out of 16 (44%) tumors expressing all SSTRs and 14 out of 16 (87%)
tumors positive for at least 3 subtypes. SSTR2A was the most represented subtype in the tumors studied, being expressed in approximately 70% of cases exhibiting an intense
labeling in most of these cases. The significant expression of SSTRs shown in this series of GISTs and gastrointestinal leiomyosarcomas
suggests a potential therapeutic target to be explored alone and/or in combination with other therapeutic agents in the setting
of refractory GI stromal tumors. |
| |
| Keywords: | : GIST – Gastrointestinal leiomyosarcomas – Tissue transglutaminase – Somatostatin receptor – Immunohistochemistry – Imatinib |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
